Development of NAFLD ‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation
Progressive non‐alcoholic fatty liver disease (NAFLD) may culminate in severe complications, including fibrosis, cirrhosis and hepatocellular carcinoma, yet therapeutic breakthroughs remain elusive, necessitating novel pharmacological strategies. Semaglutide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist clinically approved for type 2 diabetes and obesity management, has demonstrated pleiotropic effects in preclinical NAFLD models. In this study, we investigated semaglutide's therapeutic efficacy and mechanisms in a human liver organoids (hLOs) model of NAFLD. Utilising microengineered array chips, human induced pluripotent stem cells (hiPSCs) were differentiated into hLOs with functional hepatic properties. NAFLD pathology was induced via free fatty acid (FFA) exposure, recapitulating disease hallmarks such as steatosis, inflammatory cytokine elevation and fibrogenic activation. Semaglutide treatment at 50 nM significantly attenuated lipid deposition caused by FFAs and reduced triglyceride levels by 8‐fold and cholesterol levels by 1.8‐fold. It also inhibited the expression of pro‐inflammatory markers (IL‐6, IL‐8, TNF‐α) by about 1.5–2 fold and increased the level of lipolytic genes by about 45%. These findings elucidate the therapeutic potential of semaglutide in attenuating key NAFLD‐associated pathologies and establish a robust in vitro platform for preclinical drug evaluation. The study provides critical insights into targeted NAFLD interventions and supports the translation of GLP‐1‐based therapies into clinical practice, addressing an unmet need in hepatology.
No keywords indexed for this article. Browse by subject →
Natasha Chidekel Bergmann, Melanie J. Davies, Ildiko Lingvay et al.
Marta B. Afonso, Vanda Marques, Saskia W.C. van Mil et al.
Cynthia Lebeaupin, Deborah Vallée, Younis Hazari et al.
Riccardo Nevola, Raffaella Epifani, Simona Imbriani et al.
- Published
- Aug 27, 2025
- Vol/Issue
- 59(4)
- License
- View
You May Also Like
L. Ouyang, Z. Shi · 2012
1,150 citations
Yang An, Shuyan Lin · 2021
395 citations
Yaxing Chen, Chen Qin · 2020
273 citations
Xiao‐Ru Shao, Xue‐Qin Wei · 2015
271 citations